Royalty Pharma To Acquire Royalties And Milestones On Frexalimab Owned By ImmuNext For ~$525M In Cash Including Estimated Transaction Costs
Portfolio Pulse from Benzinga Newsdesk
Royalty Pharma (RPRX) is set to acquire royalties and milestones on frexalimab from ImmuNext for approximately $525 million in cash, including estimated transaction costs. This deal grants Royalty Pharma 100% of net royalties on worldwide net sales of frexalimab up to $2.0 billion, with a share of royalties above this threshold going to ImmuNext shareholders. The acquisition also includes potential milestone payments from Sanofi (SNY), with frexalimab's royalties projected through 2041. Frexalimab, developed by Sanofi, is a pioneering anti-CD40 ligand monoclonal antibody.
May 09, 2024 | 11:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Royalty Pharma's acquisition of frexalimab royalties and milestones for $525M could significantly boost future revenues, with exclusive rights to net royalties on sales up to $2B and potential milestone payments.
This acquisition is directly related to Royalty Pharma's future revenue streams, making it highly relevant and important for investors. The deal's potential to significantly boost revenues through royalties and milestone payments justifies a positive score.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Sanofi's development of frexalimab, a first-in-class anti-CD40 ligand monoclonal antibody, could see enhanced value from Royalty Pharma's acquisition, with milestone payments contributing to its revenue.
Sanofi stands to benefit from milestone payments as part of Royalty Pharma's acquisition of frexalimab royalties. This deal highlights the value of Sanofi's pipeline and could positively impact its revenue, justifying a positive score.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 70